newsfilter
← Latest News
GlobeNewswire·

Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Takeda to accelerate leadership role in advancing FIN-524/TAK-524 ulcerative colitis development program Topline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in open label PRISM-EXT trial expected in H2 2021 Co